BC Innovations | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BC Innovations | Aug 30, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Chemerin; chemokine-like receptor 1 (CMKLR1; ChemR23) Patient and mouse studies suggest increasing chemerin signaling could help treat melanoma. In patients with melanoma, high levels...
BC Week In Review | Feb 13, 2012
Clinical News

CCX832: Development discontinued

ChemoCentryx disclosed in an SEC filing that it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) will discontinue development of CCX832 and its 2 backup compounds. ChemoCentryx said the decision was based on unblinded data...
BioCentury | Feb 13, 2012

Calculating ChemoCentryx

The experience of ChemoCentryx Inc. provides more evidence that preclinical-stage Verastem Inc. 's bumped up IPO and $202.3 million valuation isn't a measuring stick for biotechs looking to go public. Indeed, investors took a pound...
BC Extra | Feb 7, 2012
Clinical News

ChemoCentryx, GSK discontinue ChemR23 antagonist

ChemoCentryx Inc. (Mountain View, Calif.) said it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will discontinue development of CCX832 and its two backup compounds. ChemoCentryx said the decision was based on unblinded data from a Phase...
BC Week In Review | Feb 7, 2011
Clinical News

CCX832: Phase I started

ChemoCentryx began a placebo-controlled, dose-escalation, Swiss Phase I trial to evaluate CCX832 in healthy volunteers. The trial start triggers a $10 million milestone payment from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) under a 2006 deal...
BioCentury | Jan 31, 2011
Product Development

Safety in psoriasis

Psoriasis has become a crowded space, with more than 60 products in Phase II and beyond. ChemoCentryx Inc. hopes its CCX832 will be more effective than topicals that are good only for mild psoriasis, without...
BC Innovations | Aug 12, 2010
Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche 's Genentech Inc. unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease. 1 Nineteen of the 112 candidate...
BC Innovations | Apr 22, 2010
Targets & Mechanisms

Promoting pain resolution

Harvard Medical School researchers have shown that resolvins could help treat inflammatory pain without the side effects associated with opioids and COX-2 inhibitors. 1 The findings could open up a new indication for Resolvyx Pharmaceuticals...
BC Week In Review | Apr 19, 2010
Company News

ChemoCentryx, GlaxoSmithKline deal

ChemoCentryx received a $5 million milestone payment from GlaxoSmithKline under a 2006 deal that gave the pharma an option to license up to six products developed by ChemoCentryx against four chemokine and chemoattractant receptors. The...
Items per page:
1 - 10 of 11